-
Signature
-
/s/ James R. Oehler, Attorney-in-Fact
-
Issuer symbol
-
HALO
-
Transactions as of
-
10 Nov 2025
-
Net transactions value
-
-$4,167,930
-
Form type
-
4
-
Filing time
-
12 Nov 2025, 18:54:37 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Torley Helen |
PRESIDENT AND CEO, Director |
C/O HALOZYME THERAPEUTICS, INC., 12390 EL CAMINO REAL, SAN DIEGO |
/s/ James R. Oehler, Attorney-in-Fact |
12 Nov 2025 |
0001528185 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
HALO |
Common Stock |
Options Exercise |
$162,200 |
+20,000 |
+2.7% |
$8.11 |
753,719 |
10 Nov 2025 |
Direct |
F1 |
| transaction |
HALO |
Common Stock |
Sale |
$1,367,409 |
-19,900 |
-2.6% |
$68.71 |
733,819 |
10 Nov 2025 |
Direct |
F1, F2 |
| transaction |
HALO |
Common Stock |
Sale |
$6,930 |
-100 |
-0.01% |
$69.30 |
733,719 |
10 Nov 2025 |
Direct |
F1 |
| transaction |
HALO |
Common Stock |
Options Exercise |
$162,200 |
+20,000 |
+2.7% |
$8.11 |
753,719 |
11 Nov 2025 |
Direct |
F1 |
| transaction |
HALO |
Common Stock |
Sale |
$305,514 |
-4,500 |
-0.6% |
$67.89 |
749,219 |
11 Nov 2025 |
Direct |
F1, F3 |
| transaction |
HALO |
Common Stock |
Sale |
$275,180 |
-4,000 |
-0.53% |
$68.80 |
745,219 |
11 Nov 2025 |
Direct |
F1, F4 |
| transaction |
HALO |
Common Stock |
Sale |
$801,906 |
-11,500 |
-1.5% |
$69.73 |
733,719 |
11 Nov 2025 |
Direct |
F1, F5 |
| transaction |
HALO |
Common Stock |
Options Exercise |
$162,200 |
+20,000 |
+2.7% |
$8.11 |
753,719 |
12 Nov 2025 |
Direct |
F1 |
| transaction |
HALO |
Common Stock |
Sale |
$893,033 |
-12,718 |
-1.7% |
$70.22 |
741,001 |
12 Nov 2025 |
Direct |
F1, F6 |
| transaction |
HALO |
Common Stock |
Sale |
$482,268 |
-6,784 |
-0.92% |
$71.09 |
734,217 |
12 Nov 2025 |
Direct |
F1, F7 |
| transaction |
HALO |
Common Stock |
Sale |
$35,690 |
-498 |
-0.07% |
$71.67 |
733,719 |
12 Nov 2025 |
Direct |
F1, F8 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
HALO |
Option to Purchase Common Stock |
Options Exercise |
$162,200 |
-20,000 |
-26% |
$8.11 |
56,569 |
10 Nov 2025 |
Common Stock |
20,000 |
$8.11 |
Direct |
F1, F9 |
| transaction |
HALO |
Option to Purchase Common Stock |
Options Exercise |
$162,200 |
-20,000 |
-35% |
$8.11 |
36,569 |
11 Nov 2025 |
Common Stock |
20,000 |
$8.11 |
Direct |
F1, F9 |
| transaction |
HALO |
Option to Purchase Common Stock |
Options Exercise |
$162,200 |
-20,000 |
-55% |
$8.11 |
16,569 |
12 Nov 2025 |
Common Stock |
20,000 |
$8.11 |
Direct |
F1, F9 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: